10-Q: Sunshine Biopharma Narrows Q3 Loss, Boosts Revenue

Sunshine Biopharma Inc. reported an 11.6% increase in Q3 2025 revenue and a 24.0% reduction in net loss, driven by enhanced marketing and improved cost of goods sold.

Summary

• Revenue for the three months ended September 30, 2025, increased by 11.6% to $9,417,179 compared to $8,435,178 in the prior year period.
• Net loss for the three months ended September 30, 2025, decreased by 24.0% to $(883,820) or $(0.19) per share, from $(1,197,803) or $(0.94) per share in the same period of 2024.
• For the nine months ended September 30, 2025, revenue increased by 9.7% to $27,728,750 compared to $25,279,291 in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $(3,834,425) or $(0.98) per share, from $(2,975,904) or $(13.61) per share in the prior year, primarily due to a $1,616,459 impairment of intangible assets.
• Cash and cash equivalents totaled $9,306,438 as of September 30, 2025.
• Net cash used in operating activities significantly decreased to $(3,715,067) for the nine months ended September 30, 2025, from $(9,119,519) in the prior year.
• The company terminated Mr. Malek Chamoun, former president of its Canadian subsidiary Nora Pharma, on April 14, 2025, leading to a disputed earnout balance of $295,797 USD and a demand letter for $7,307,025 CAD (approximately $5,300,000 USD).
• Proprietary drug development programs, K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections, are in animal testing stages, with SBFM-PL4 showing positive results and published research.
• The company has 76 generic prescription drugs on the market in Canada and anticipates launching 12 additional drugs in 2026.

Sentiment

Score: 6

Explanation: The company shows positive revenue growth and a reduced quarterly net loss, alongside progress in drug development. However, the increased nine-month net loss due to a significant intangible asset impairment, an ongoing material legal dispute, and the explicit need for future capital raises introduce considerable uncertainty and temper the overall sentiment.

Positives

• Q3 2025 revenue increased by 11.6% year-over-year to $9,417,179, demonstrating continued sales growth.
• Q3 2025 net loss decreased by 24.0% year-over-year to $(883,820), indicating improved quarterly profitability.
• Nine-month revenue increased by 9.7% year-over-year to $27,728,750, attributed to enhanced marketing efforts.
• Cost of goods sold as a percentage of revenue improved for the nine-month period, decreasing from 70.0% in 2024 to 66.7% in 2025 due to better procurement.
• Net cash used in operating activities significantly decreased to $(3,715,067) for the nine months ended September 30, 2025, from $(9,119,519) in the prior year, reflecting reduced cash requirements for Nora Pharma operations.
• Proprietary drug development programs, K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus, are progressing, with SBFM-PL4 showing positive animal testing results and published research.
• The company maintains a portfolio of 76 generic prescription drugs on the Canadian market and has 12 additional drugs anticipated for launch in 2026, strengthening its market presence.
• Management believes existing cash on hand and cash generated from sales will be sufficient to fund operations for the next 24 months.

Negatives

• Nine-month net loss increased to $(3,834,425) from $(2,975,904) in the prior year, primarily due to a significant $1,616,459 impairment of intangible assets.
• General and administrative expenses increased by $2,312,706 for the nine-month period, largely driven by the intangible asset impairment.
• Interest income decreased for both the three-month and nine-month periods due to changes in interest rates and having less cash on hand.
• A significant legal dispute with former Nora Pharma president, Mr. Malek Chamoun, involves a demand for $7,307,025 CAD (approximately $5,300,000 USD), with the company intending to defend itself vigorously.
• The company has recorded valuation allowances against the majority of its deferred tax assets, indicating uncertainty about future earnings.
• The company has no committed sources of capital and anticipates needing to raise additional capital in the future.
• The company reversed its decision to invest $5 million of cash on hand in Bitcoin due to recent volatility.

Risks

• Generic drug prices are highly dependent on government policies in Canada, which may change over time, impacting the company's revenue and profitability.
• The company's proprietary drug development programs (K1.1 mRNA and SBFM-PL4) are in early stages (animal testing), and there is no assurance of successful development, regulatory approval, or commercialization.
• The company has no committed sources of capital and may not be able to raise additional capital on acceptable terms or at all, which is necessary for future research and development activities, potential clinical trials, and expansion of generic pharmaceutical operations.
• Legal proceedings related to the termination of Mr. Malek Chamoun and the disputed earnout amount could result in significant liabilities or legal expenses, which have not been accrued in the financial statements.
• Management's estimates regarding future funding sufficiency (24 months of operations) may not be accurate, potentially leading to earlier than anticipated capital needs.
• Uncertainty regarding future earnings, as indicated by the company's decision to maintain valuation allowances against the majority of its deferred tax assets.

Future Outlook

The company anticipates launching 12 additional generic drugs in 2026 to strengthen its presence in the Canadian generic drug market. Management is focused on increasing sales, streamlining operations, and lowering the cost of goods sold from approximately 67% to 60% to achieve breakeven and reduce dependence on capital markets. Existing cash and sales are expected to fund operations for the next 24 months, but additional capital will be needed for future R&D, potential clinical trials, and expansion of generic pharmaceutical operations.

Management Comments

• We are currently generating revenue of approximately $9.4 million per quarter and incurring a quarterly deficit of approximately $1.0 million.
• We are currently focusing our attention on lowering our cost of goods sold from our current level of approximately 67% to approximately 60%.
• We believe these measures could bring us to breakeven and make us less dependent on the capital markets for financing, although there can be no assurances that we will be successful in achieving these reductions.
• We believe our existing cash on hand together with cash we generate from sales will be sufficient to fund our operations for the next 24 months. There is no assurance our estimates will be accurate.
• We have no committed sources of capital and we anticipate that we will need to raise additional capital in the future, including for further research and development activities and possibly clinical trials, as well as expansion of our generic pharmaceutical operations.

Industry Context

The company operates in the Canadian generic drug market, which is valued at $9.7 billion annually. The Canadian federal government's recent participation in the generic drug reimbursement program under the Pharmacare Act is expected to further strengthen this market, which is the company's primary commercial focus. The company's proprietary drug development in oncology and antivirals places it in highly competitive and capital-intensive segments of the biopharmaceutical industry, where successful innovation can yield significant returns but also carries substantial risk.

Comparison to Industry Standards

• The Canadian generic drug market is cited as a $9.7 billion annual market (Research and Markets), providing a significant addressable market for the company's 76 existing and 12 pipeline generic drugs.
• The SBFM-PL4 compound is being developed as a first-in-class PLpro inhibitor to treat SARS-CoV2 and potentially SARS-CoV and MERS-CoV infections, specifically targeting patients who cannot use existing treatments like Paxlovid, Molnupiravir, or Remdesivir due to drug interactions or side effects.
• The K1.1 mRNA oncology program is in animal testing, which is a standard preclinical stage for novel cancer therapeutics, with initial results showing effectiveness in reducing liver cancer tumors in xenograft mice.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings, except for a dispute with former Nora Pharma president, Mr. Malek Chamoun.
• On April 17, 2025, a demand letter was received from Mr. Chamoun's attorneys requesting $7,307,025 CAD (approximately $5,300,000 USD) within five days.
• The company responded on May 1, 2025, stating the demands are unfounded and intends to defend itself vigorously.
• No provision or accrual was made in the financial statements for any litigation liability or legal expense related to this alleged claim.

Related Party Transactions

• The CEO holds 130,000 shares of Series B Preferred Stock, which carry 1,000 votes per share.
• On February 8, 2024, 20,000 shares of Series B Preferred Stock were issued to the CEO for $0.10 per share.
• On March 4, 2024, 100,000 shares of Series B Preferred Stock were issued to the CEO for $0.10 per share.
• $400,000 of officer compensation for the nine months ended September 30, 2024, was paid to Advanomics Corporation, a company controlled by the CEO.
• A disputed earnout amount of $295,797 USD (originally $5,000,000 CAD) is payable to Mr. Malek Chamoun, the seller of Nora Pharma and former president of the subsidiary.

Stakeholder Impact

• Shareholders: Potential for increased value from revenue growth and drug development, but diluted by ongoing losses, the explicit need for future capital raises, and potential legal liabilities. Per-share metrics have been significantly impacted by reverse stock splits.
• Employees: Change in leadership at Nora Pharma with the termination of Mr. Malek Chamoun and appointment of Ms. Catherine Peloquin.
• Customers (Pharmacies in Canada): Continued supply of 76 generic prescription drugs and anticipated expansion with 12 new drugs in 2026.
• Creditors: The company has current liabilities of $6,651,315 and long-term liabilities of $636,708. The legal dispute with Mr. Chamoun could create a significant contingent liability.
• Suppliers: The company's focus on lowering cost of goods sold may impact supplier relationships or negotiations.

Next Steps

• Confirm results of K1.1 mRNA-LNP constructs in additional xenograft experiments and more detailed dose-response studies.
• Prepare a new manuscript describing the latest research results on the SBFM-PL4 lead compound.
• Launch 12 additional generic drugs in 2026.
• Increase sales and streamline operations to reduce expenses.
• Lower cost of goods sold from approximately 67% to approximately 60%.
• Defend against the demand letter from Mr. Malek Chamoun regarding the disputed earnout and alleged claims.
• Evaluate the potential impact of adopting ASU 2023-09 (Income Tax Disclosures) for the Annual Report on Form 10-K for the year ending December 31, 2025.
• Evaluate the potential impact of adopting ASU 2024-03 (Income Statement Expense Disaggregation) for the Annual Report on Form 10-K for the year ending December 31, 2027.
• Raise additional capital for R&D, potential clinical trials, and expansion of generic pharmaceutical operations.

Key Dates

Recommendation

The company demonstrates positive revenue growth in its generic drug segment and progress in its proprietary drug development pipeline, along with a reduced quarterly net loss and improved operating cash flow. However, the increased nine-month net loss due to a significant intangible asset impairment, the explicit need for future capital raises, and a material legal dispute with a former executive introduce considerable uncertainty and risk. Investors should hold and monitor the resolution of the legal dispute, the success of cost-reduction efforts, and further progress in drug development before making additional investment decisions.

Keywords

Biopharma, Pharmaceuticals, Generic Drugs, Oncology, Antivirals, Liver Cancer, SARS Coronavirus, K1.1 mRNA, SBFM-PL4, Nora Pharma, SEC Filing, 10-Q, Financial Results, Drug Development, Canada, Biotechnology